|
|
10 Forge Parkway
Franklin, MA 02038 United States
phone:(508) 553-8850
fax:(508) 553-8760
|
|
| Symbol |
ECTE |
| Exchange |
OTCBB |
| Founded |
1989 |
| Employees |
24 |
|
|
| www.echotx.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Transdermal medical device and specialty pharmaceuticals company. |
|
| Management |
| Patrick T. Mooney MD, Chairman & Chief Executive Officer; Harry G. Mitchell, Chief Operating Officer and Chief Financial Officer; Shawn K. Singh, JD, President |
| |
|
|
|
|
|
|
|
| Keywords |
| transdermal medication, drugs, ultrasonic, drug delivery, DrugDelivery |
|
|
|
| Description |
|
Echo Therapeutics is a medical device and specialty pharmaceutical company developing a non-invasive (needle-free) and wireless transdermal continuous glucose monitoring (tCGM) system for diabetic patients. The company also possesses a pipeline of novel topical reformulations of FDA-approved pharmaceuticals. |
|
| Products / Services |
With the Symphony tCGM, Echo Therapeutics has demonstrated its goal to reduce reliance on periodic point-of-care finger-stick glucose testing by providing reliable on-demand data in a continuous, convenient and cost-effective manner. The company hopes its non-invasive technology will improve patient compliance and enable patients to achieve better overall glucose control day and night. Echo is also leveraging its patented AzoneTS transdermal drug reformulation technology to build a pipeline of novel topical reformulations of FDA-approved products. Durhalieve, Echo's lead AzoneTS drug candidate, is a topical reformulation of the corticosteroid triamcinolone acetonide. Additionally, Echo's FDA-cleared SonoPrep uses non-invasive ultrasonic skin permeation technology for painless and transdermal drug delivery.
|
|
| Technology / Differentiation |
| Echo's Symphony tCGM System incorporates Echo's patented feedback mechanism for optimal skin permeation control and its non-invasive, continuous transdermal biosensor. AzoneTS is a non-toxic penetration enhancer known to increase lipid membrane fluidity in the stratum corneum (outermost layer of the skin), thereby decreasing the diffusion resistance to topically applied therapeutics by two to more than twenty fold. In addition to Durhalieve, Echo Therapeutics is developing additional AzoneTS product candidates in accordance with the FDA's Section 505(b)(2) guidelines. Echo's ultrasound-mediated skin permeation technology enhances the fluids and molecules across the protective membrane of the stratum corneum. An application of SonoPrep increases skin permeation to one hundred times greater than untreated skin, facilitating the transdermal delivery of large molecule drugs. |
|
| Market / Customers |
Echo Therapeutics primarily markets its products through independent medical device distributors in the United States. Its Symphony tCGM is intended for home use and use within the hospital critical care sector. Diabetes is the sixth leading cause of death in the United States; over $100 billion is spent annually in the United States for the direct and indirect costs of treating diabetes.
|
|
| Strategy |
The company intends to expand the application of its SonoPrep technology to detect and measure other analytes, such as alcohol and other blood chemistries, that are traditionally measured by sending blood samples to the lab for analysis.
|
|
| Status |
| Echo received FDA 510(k) marketing clearance in February 2004 for the use of Sonoprep in electrophysiology applications. On October 16, 2008, the company announced the issuance of a U.S. patent covering the composition and preparation methods of a polyethylene glycol (PEG)-based hydrogel, a key component of Echo's Symphony tCGM system. Echo announced positive results in November 2008 from its most recent clinical trial of the Symphony system in type I and II diabetic patients. Additionally, the company has submitted a New Drug Application (NDA) covering Durhalieve as a proprietary treatment for corticosteroid responsive dermatoses and plans to submit an Investigational New Drug (IND) application to commence Phase 2 clinical development of this drug candidate for the treatment of keloid and hypertrophic scarring. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members